Cell or exosome application is a clinic procedure (15–30 minutes); patients continue outpatient care immediately. Healing progression—measurable wound-area reduction—typically emerges within 2–3 weeks and continues over 8–12 weeks. Patients must continue pressure offloading, glucose control, and vascular care throughout.
Chronic wound cell and exosome therapy has been subject to 59 completed trials, with 7 currently enrolling participants. Trials span diabetic foot ulcers (majority), pressure wounds, and mixed aetiology chronic wounds. Closure rates (percentage of wounds achieving full epithelial coverage) in treated cohorts typically range from 55–85% over 8–16 weeks, compared to reported historical control rates of 20–40% for advanced wounds. Exosome-based studies specifically show wound-area reduction averaging 45–70% at 12 weeks. Trial heterogeneity in wound selection, cell dose, and delivery (topical, intradermal injection, or fibrin-scaffold embedding) limits meta-analysis.
Bin ich ein Kandidat? → · Chronic Wounds & Ulcers: full overview → · Chronische Wunden und Geschwüre Kosten → · Cost →
Medizinisch geprüft vom Redaktionsteam von StemCellAtlas zusammen mit the Stem Plus medical team (physicians & scientists · GMP-certified Sofia laboratory · 25+ yrs international experience) der Partnerklinik Stem Plus (Sofia), gemäß ISSCR-, FDA- und EMA-Leitlinien. Educational information, not medical advice; figures indicative.
GMP-zertifizierte regenerative Medizin mitten in der EU — ab 3.000–8.000 €, ein Bruchteil der US- oder Deutschland-Preise. Individuelle Protokolle für internationale Patienten aus über 50 Ländern.
Kostenlose ärztliche Prüfung